CMB International has released a research report, raising the price target for SKB BIO (06990) by 0.5%, from HK$642.99 to HK$645.62, while maintaining a 'Buy' rating.
The bank stated that, given the smooth progress in the development of sac-TMT, it has raised its DCF-based price target from HK$642.29 to HK$645.62.
Near-term catalysts include the ASCENT-GYN readout around the end of 2026, the approval progress of sac-TMT in EC, further TroFuse Phase III data in 2027, and the initiation of a Phase III study of MK-2010 combined with sac-TMT in the first half of 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments